Genfit price target raised to $9 from $8 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Genfit to $9 from $8 and keeps a Buy rating on the shares. The analyst is confident that elafibranor hits the primary endpoint in ELATIVE, and expects the readout to "represent a major stock catalyst."